• Treffer 4 von 4
Zurück zur Trefferliste

Prevalence of pretreatment HIV drug resistance in Mwanza, Tanzania

Zitieren Sie bitte immer diese URN: urn:nbn:de:bvb:20-opus-227124
  • Background: In a 2008-10 study, we found a pretreatment HIV drug resistance (PDR) prevalence of 18.2% in patients at Bugando Medical Centre (BMC) in Mwanza, Tanzania. Objectives: To determine the prevalence of PDR and transmitted HIV drug resistance (TDR) in patients visiting the BMC from 2013 to 2015. Methods: Adult outpatients were sequentially enrolled into two groups, separated by whether they were initiating ART. Previous exposure to antiretroviral drugs, except for prevention of mother-to-child transmission, was an exclusionBackground: In a 2008-10 study, we found a pretreatment HIV drug resistance (PDR) prevalence of 18.2% in patients at Bugando Medical Centre (BMC) in Mwanza, Tanzania. Objectives: To determine the prevalence of PDR and transmitted HIV drug resistance (TDR) in patients visiting the BMC from 2013 to 2015. Methods: Adult outpatients were sequentially enrolled into two groups, separated by whether they were initiating ART. Previous exposure to antiretroviral drugs, except for prevention of mother-to-child transmission, was an exclusion criterion. HIV pol sequences were analysed according to WHO guidelines for surveillance of PDR and TDR. Results: Two hundred and thirty-five sequences were analysed (138 ART initiators, 97 non-initiators). The prevalence of PDR was 4.7% (95% CI 2.6%-8.2%) overall, 3.1% (95% CI 1.1%-8.7%) for non-initiators and 5.8% (95% CI 3.0%-11.0%) for ART initiators. PDR to NNRTIs and nucleoside or nucelotide reverse transcriptase inhibitors was found in 3.0% (95% CI 1.5%-6.0%) and 1.7% (95% CI 0.7%-4.3%) of patients, respectively. Resistance to PIs was not observed. The prevalence of TDR was 6.0% (95% CI 3.6%-9.8%). Conclusions: Prevalence of PDR significantly decreased compared with 2008-10 and was below the WHO-defined threshold for triggering a public health response. National and systematic surveillance is needed to inform Tanzania's public health strategy.zeige mehrzeige weniger

Volltext Dateien herunterladen

Metadaten exportieren

Weitere Dienste

Teilen auf Twitter Suche bei Google Scholar Statistik - Anzahl der Zugriffe auf das Dokument
Metadaten
Autor(en): Ladius Rudovick, Jan M. Brauner, Johanna Englert, Carolina Seemann, Karina Plugaru, Benson R. Kidenya, Samuel E. Kalluvya, Carsten Scheller, Christa Kasang
URN:urn:nbn:de:bvb:20-opus-227124
Dokumentart:Artikel / Aufsatz in einer Zeitschrift
Institute der Universität:Medizinische Fakultät / Institut für Virologie und Immunbiologie
Sprache der Veröffentlichung:Englisch
Titel des übergeordneten Werkes / der Zeitschrift (Englisch):Journal of Antimicrobial Chemotherapy
Erscheinungsjahr:2018
Band / Jahrgang:73
Heft / Ausgabe:12
Seitenangabe:3476-3481
Originalveröffentlichung / Quelle:J Antimicrob Chemother 2018; 73: 3476–3481
DOI:https://doi.org/10.1093/jac/dky332
Allgemeine fachliche Zuordnung (DDC-Klassifikation):6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit
Freie Schlagwort(e):HIV; adult; anti-hiv agents; anti-retroviral agents; child; exclusion criteria; guidelines; medical; mothers; non-nucleoside reverse transcriptase inhibitors; nucleosides; outpatients; prevention; public health medicine; reverse transcriptase inhibitors; surveillance; tanzania; world health organization
Datum der Freischaltung:30.01.2023
Lizenz (Deutsch):License LogoCC BY-NC: Creative-Commons-Lizenz: Namensnennung, Nicht kommerziell 4.0 International